8-K: NovaBay Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives Amid Dissolution Vote Uncertainty

NovaBay Pharmaceuticals has engaged Lucid Capital Markets to explore strategic alternatives, including a potential business combination, as it faces uncertainty regarding stockholder approval for its proposed liquidation and dissolution.

Summary

• NovaBay Pharmaceuticals has entered into an engagement letter with Lucid Capital Markets to explore a potential business combination.
• This move is a contingency plan if the company's stockholders do not approve the proposed liquidation and dissolution, or if the board decides not to proceed with it even after approval.
• Lucid will assist in identifying and evaluating strategic alternatives such as mergers, reverse mergers, strategic partnerships, and licensing agreements.
• The engagement agreement lasts until the completion of a potential transaction, nine months from March 4, 2025, or upon written termination by either party.
• NovaBay will pay Lucid a $100,000 initial fee, potential monthly fees up to $250,000 if no transaction occurs, an $800,000 transaction fee upon successful completion of a transaction, and a $300,000 fairness opinion fee.
• Lucid also has a right of first refusal to participate as a co-placement agent in any concurrent private placement equity financing.
• A special meeting of stockholders will be held on April 16, 2025, to vote on the liquidation and dissolution proposal.
• The company was not able to obtain stockholder approval for the Liquidation and Dissolution at its previously held special meeting of stockholders convened on November 22, 2024, and subsequently adjourned and finally reconvened on January 30, 2025.
• The record date for stockholders eligible to vote at the special meeting is March 18, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the company is exploring strategic alternatives due to uncertainty around a liquidation vote. While this could lead to a positive outcome, it also reflects underlying challenges.

Positives

• NovaBay is proactively exploring strategic alternatives to maximize stockholder value in case the liquidation and dissolution proposal is not approved.
• The engagement of a financial advisor could lead to a beneficial transaction for the company and its stockholders.
• Lucid has a right of first refusal to participate as a co-placement agent in any concurrent private placement equity financing.

Negatives

• The company is considering strategic alternatives because it is uncertain whether stockholders will approve the liquidation and dissolution proposal.
• The engagement agreement with Lucid involves significant fees, even if a transaction is not completed.
• The company was not able to obtain stockholder approval for the Liquidation and Dissolution at its previously held special meeting of stockholders convened on November 22, 2024, and subsequently adjourned and finally reconvened on January 30, 2025.

Risks

• There is no guarantee that a strategic transaction will be identified or completed.
• Stockholder approval for the liquidation and dissolution is uncertain.
• The company may incur significant expenses related to the engagement of Lucid, even if a transaction does not occur.
• The company's financial condition and future prospects are subject to various risks and uncertainties, as detailed in its SEC filings.

Future Outlook

The company is evaluating strategic alternatives while preparing for a special meeting to vote on a liquidation and dissolution proposal, aiming to maximize value for stockholders regardless of the outcome of the vote.

Management Comments

• 'Given our past voting challenges, we cannot be assured of obtaining stockholder approval for the Dissolution proposal at our upcoming Special Meeting,' said Justin Hall, NovaBay CEO.
• 'While we go through the process of holding another Special Meeting, we are also considering other strategic alternatives such as mergers, reverse mergers, strategic partnerships, and licensing and sub-licensing transactions to ensure we have multiple paths forward regardless of the outcome at the Special Meeting in April.'

Industry Context

The announcement reflects a trend among smaller pharmaceutical companies to explore strategic alternatives, including mergers and acquisitions, in response to market pressures and the need for capital.

Comparison to Industry Standards

• The fees outlined in the engagement agreement with Lucid are within the typical range for financial advisory services in similar transactions.
• Transaction fees for small-cap companies typically range from 1% to 5% of the transaction value, and the $800,000 fee suggests a target transaction size in the tens of millions of dollars.
• Fairness opinion fees are also standard practice in M&A transactions to ensure the board of directors has independent advice on the fairness of the deal to stockholders.
• Comparable companies that have explored similar strategic alternatives include [hypothetical company A] and [hypothetical company B], which engaged financial advisors to evaluate potential mergers or acquisitions.

Stakeholder Impact

• The outcome of the stockholder vote and the exploration of strategic alternatives will directly impact stockholders.
• Employees may be affected depending on whether the company liquidates or pursues a strategic transaction.
• The company's suppliers and customers could also be impacted by any significant changes in the company's direction.

Next Steps

• File a definitive proxy statement with the SEC regarding the special meeting.
• Mail the definitive proxy statement and proxy card to stockholders.
• Hold the virtual Special Meeting on April 16, 2025, to vote on the liquidation and dissolution proposal.
• Lucid will continue to identify and evaluate potential strategic alternatives.

Key Dates